GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Anthera Pharmaceuticals, Inc. (ANTH) [hlAlert]

Rating:
Buy ANTH
down 85.85 %

Anthera Pharmaceuticals, Inc. (ANTH) rated Buy with price target $13 by Collins Stewart

Posted on: Friday,  Dec 2, 2011  9:25 AM ET by Collins Stewart

Collins Stewart rated Buy Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) on 12/02/2011, when the stock price was $53.36. Since
then, Anthera Pharmaceuticals, Inc. has lost 85.85% as of 01/13/2016's recent price of $7.55.
If you would have followed this Collins Stewart's recommendation on ANTH, you would have lost 85.85% of your investment in 1503 days.

Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

Collins Stewart's research department is built around a number of sector-specialist teams. Our analysts are leaders in their area of specialisation and combine deep industry knowledge with decades of stock broking experience to produce insightful, independent sector research. Our research approach encompasses Questâ„¢ principles and focuses on cash-driven valuation techniques. Research is a Collins Stewart cornerstone; it is leveraged throughout the organisation.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/2/2011 9:25 AM Buy
None
53.36 104.00
as of 12/30/2011
1 Week up  1.32 %
1 Month down  -7.94 %
3 Months   
1 YTD down  -7.94 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy